S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind

ImmunoGen Stock Price, News & Analysis (NASDAQ:IMGN)

$29.22
-0.10 (-0.34%)
(As of 12/4/2023 ET)
Compare
Today's Range
$29.05
$29.28
50-Day Range
$12.46
$29.35
52-Week Range
$3.61
$29.44
Volume
13.64 million shs
Average Volume
5.68 million shs
Market Capitalization
$7.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.77

ImmunoGen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
11.8% Downside
$25.77 Price Target
Short Interest
Bearish
12.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
-0.02mentions of ImmunoGen in the last 14 days
Based on 52 Articles This Week
Insider Trading
Selling Shares
$13.42 M Sold Last Quarter
Proj. Earnings Growth
414.29%
From $0.07 to $0.36 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

572nd out of 952 stocks

Pharmaceutical Preparations Industry

269th out of 434 stocks


IMGN stock logo

About ImmunoGen Stock (NASDAQ:IMGN)

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

IMGN Stock Price History

IMGN Stock News Headlines

ImmunoGen's (IMGN) "Neutral" Rating Reaffirmed at Piper Sandler
ImmunoGen downgraded to Neutral from Overweight at Piper Sandler
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
ImmunoGen (NASDAQ:IMGN) Rating Reiterated by Barclays
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
ImmunoGen (NASDAQ:IMGN) Downgraded by William Blair
ImmunoGen (NASDAQ:IMGN) Stock Rating Lowered by Guggenheim
Barclays Downgrades Immunogen (IMGN)
ImmunoGen (NASDAQ:IMGN) Sets New 52-Week High at $29.34
HC Wainwright Reaffirms Neutral Rating for ImmunoGen (NASDAQ:IMGN)
Guggenheim Downgrades Immunogen (IMGN)
Maintaining Hold on ImmunoGen Amid AbbVie Acquisition Offer
ImmunoGen Sees Unusually High Options Volume (NASDAQ:IMGN)
ImmunoGen downgraded to Hold from Buy at Canaccord
AbbVie to acquire ImmunoGen in $10B deal
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
277
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$25.77
High Stock Price Target
$31.26
Low Stock Price Target
$16.00
Potential Upside/Downside
-11.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-222,930,000.00
Pretax Margin
-25.24%

Debt

Sales & Book Value

Annual Sales
$108.78 million
Book Value
$0.71 per share

Miscellaneous

Free Float
252,764,000
Market Cap
$7.78 billion
Optionable
Optionable
Beta
1.22

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives















IMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price target for 2024?

12 Wall Street analysts have issued 12 month price targets for ImmunoGen's shares. Their IMGN share price targets range from $16.00 to $31.26. On average, they anticipate the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN shares have increased by 489.1% and is now trading at $29.22.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 32,660,000 shares, an increase of 30.5% from the October 31st total of 25,030,000 shares. Based on an average daily volume of 4,780,000 shares, the short-interest ratio is currently 6.8 days.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. The biotechnology company earned $113.43 million during the quarter, compared to the consensus estimate of $106.98 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (6.57%), RA Capital Management L.P. (5.00%), Wellington Management Group LLP (4.98%), FMR LLC (2.17%), Morgan Stanley (1.81%) and Artisan Partners Limited Partnership (1.40%). Insiders that own company stock include David G Foster, Mark J Enyedy, Renee Lentini, Stacy Ann Coen and Theresa Wingrove.
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
This page (NASDAQ:IMGN) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -